Jackson-Spence Francesca, Szabados Bernadett, Toms Charlotte, Yang Yu-Hsuen, Sng Christopher, Powles Thomas
Barts Cancer Institute, Queen Mary University of London, London, UK.
Barts Health NHS Trust, St Bartholomew's Hospital West Smithfield London, London, UK.
Expert Rev Anticancer Ther. 2022 Feb;22(2):135-140. doi: 10.1080/14737140.2022.2028621. Epub 2022 Jan 20.
Outcomes for patients with advanced or metastatic urothelial carcinoma (UC) remain poor. Targeting the programmed death ligand-1 (PD-(L)1) immune checkpoint pathway has emerged as a useful target in patients with UC. Avelumab is a PD-L1 inhibitor, resulting in restoration of a cytotoxic, antitumor T cell response. Results from the JAVELIN bladder 100 trial has resulted in a new standard of care of platinum-based chemotherapy sequenced by maintenance avelumab in advanced or metastatic UC.
This review covers the clinical evidence for avelumab in UC. This includes the maintenance approach with avelumab, which has become the standard of care, following platinum-based chemotherapy.
Immune checkpoint inhibitor treatment in metastatic UC holds much promise, but has not been optimized. First-line maintenance avelumab is an attractive option for these patients. Future research will significantly change the landscape of treatment in the near future.
晚期或转移性尿路上皮癌（UC）患者的预后仍然很差。靶向程序性死亡配体-1（PD-(L)1）免疫检查点通路已成为UC患者的一个有效靶点。阿维鲁单抗是一种PD-L1抑制剂，可恢复细胞毒性抗肿瘤T细胞反应。JAVELIN膀胱100试验的结果导致了晚期或转移性UC的一种新的护理标准，即铂类化疗后序贯使用阿维鲁单抗维持治疗。
本综述涵盖了阿维鲁单抗在UC中的临床证据。这包括阿维鲁单抗的维持治疗方法，该方法在铂类化疗后已成为护理标准。
转移性UC的免疫检查点抑制剂治疗前景广阔，但尚未得到优化。一线阿维鲁单抗维持治疗对这些患者来说是一个有吸引力的选择。未来的研究将在不久的将来显著改变治疗格局。
